Get the Stockscreener App
49.48
1.85%
-0.88
Avidity Biosciences Inc stock is traded at $49.48, with a volume of 1.32M.
It is down -1.85% in the last 24 hours and up +6.78% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$50.36
Open:
$48.94
24h Volume:
1.32M
Relative Volume:
0.53
Market Cap:
$6.36B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-17.12
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
+6.12%
1M Performance:
+6.78%
6M Performance:
+63.19%
1Y Performance:
+22.17%
1-Day Range:
$47.98
$50.05
1-Week Range:
$45.24
$51.40
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
49.44 | 6.48B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.55 | 101.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.79 | 59.25B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.17 | 60.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
761.42 | 45.95B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.40 | 37.61B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Why is Avidity Biosciences Inc. stock going upLayoff News & Weekly Setup with High ROI Potential - beatles.ru
Avidity Biosciences’ Phase 3 Study on AOC 1020: A Potential Breakthrough for FSHD - TipRanks
Avidity Biosciences’ Promising Phase 3 Study on Del-desiran for DM1: What Investors Need to Know - TipRanks
How to integrate Avidity Biosciences Inc. into portfolio analysis toolsProduct Launch & Fast Momentum Entry Tips - Newser
Is Avidity Biosciences Inc. stock ready for a breakoutJuly 2025 Summary & Daily Price Action Insights - Newser
Should you avoid Avidity Biosciences Inc. stock right nowJuly 2025 Earnings & Precise Swing Trade Alerts - خودرو بانک
Avidity Biosciences CEO Boyce sells $2.5 million in stock By Investing.com - Investing.com Canada
Avidity Biosciences: Chief commercial officer sells $308k in stock By Investing.com - Investing.com Canada
Sentiment analysis tools applied to Avidity Biosciences IncCEO Change & Free AI Powered Buy and Sell Recommendations - Newser
Volume spikes in Avidity Biosciences Inc. stock – what they meanMarket Movers & Safe Entry Point Alerts - Newser
Can Avidity Biosciences Inc. recover in the next quarterWeekly Investment Recap & AI Based Buy and Sell Signals - Newser
Avidity Biosciences shares rise 3.80% intraday after presenting at Cantor Global and Wells Fargo conferences. - AInvest
Take Profit: Can Avidity Biosciences Inc. outperform under higher oil pricesMarket Activity Report & Expert Verified Stock Movement Alerts - خودرو بانک
Avidity Biosciences: Pioneering RNA Therapeutics in the Race for Rare Disease Leadership - AInvest
Avidity Biosciences: Pioneering Precision in Gene Therapy with AOC Platform - AInvest
Transcript : Avidity Biosciences, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 12 - MarketScreener
Using Python tools to backtest Avidity Biosciences Inc. strategies2025 Key Lessons & AI Driven Price Predictions - Newser
Is Avidity Biosciences Inc. a top pick in the sector2025 Historical Comparison & Risk Managed Investment Entry Signals - خودرو بانک
Full technical analysis of Avidity Biosciences Inc. stockMarket Trend Summary & Consistent Income Trade Ideas - Newser
Is now a turning point for Avidity Biosciences Inc.Weekly Profit Report & Proven Capital Preservation Methods - Newser
Avidity Biosciences Inc. stock trend forecastJuly 2025 PostEarnings & Community Verified Trade Signals - Newser
Technical Heatmap Flags Avidity Biosciences Inc. for WatchJuly 2025 Sector Moves & Community Verified Swing Trade Signals - beatles.ru
What’s the RSI of Avidity Biosciences Inc. stockJuly 2025 Technicals & Technical Entry and Exit Tips - خودرو بانک
Avidity Biosciences Inc. stock momentum explainedWeekly Profit Analysis & Technical Confirmation Alerts - Newser
Is Avidity Biosciences Inc. forming a reversal patternQuarterly Performance Summary & Accurate Trade Setup Notifications - Newser
News impact scoring models applied to Avidity Biosciences Inc.Analyst Downgrade & Risk Controlled Daily Plans - Newser
Price momentum metrics for Avidity Biosciences Inc. explainedJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Technical analysis overview for Avidity Biosciences Inc. stockWeekly Investment Summary & Low Risk High Reward Trade Ideas - Newser
Order flow analysis tools used on Avidity Biosciences Inc.July 2025 Setups & High Conviction Investment Ideas - Newser
Tools to monitor Avidity Biosciences Inc. recovery probabilityTrade Risk Assessment & Advanced Swing Trade Entry Plans - Newser
Avidity Biosciences CPO sells $8914 in RNA stock By Investing.com - Investing.com South Africa
Avidity Biosciences CPO sells $8914 in RNA stock - Investing.com
Avidity Biosciences' Kathleen Gallagher Sells 188 Shares at $47.42 - AInvest
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license - Reuters
Is Avidity Biosciences Inc. stock showing strong momentumJuly 2025 Outlook & Capital Efficiency Focused Strategies - خودرو بانک
Reversal indicators forming on Avidity Biosciences Inc. stockEarnings Beat & Free Weekly Watchlist of Top Performers - Newser
Detecting price anomalies in Avidity Biosciences Inc. with AIEarnings Recap Report & Weekly High Conviction Ideas - Newser
Can Avidity Biosciences Inc. outperform under higher oil pricesJuly 2025 News Drivers & Expert Approved Trade Ideas - خودرو بانک
How to use a screener to detect Avidity Biosciences Inc. breakouts2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Momentum Shift: Can Avidity Biosciences Inc. reach resistance levels soonQuarterly Profit Summary & Reliable Price Breakout Alerts - خودرو بانک
Short Covering: Is Avidity Biosciences Inc. stock a top performer YTD2025 Price Momentum & AI Powered Trade Plan Recommendations - خودرو بانک
Analyzing recovery setups for Avidity Biosciences Inc. investorsPortfolio Value Summary & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-02 00:27:58 - خودرو بانک
Is Avidity Biosciences Inc. a potential multi baggerJuly 2025 Institutional & Stepwise Trade Execution Plans - خودرو بانک
RNA Stock Price and Chart — NASDAQ:RNA - TradingView
What moving averages say about Avidity Biosciences Inc.July 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
Does Avidity Biosciences Inc. show high probability of reboundWeekly Trend Summary & Safe Entry Point Alerts - Newser
Published on: 2025-08-31 20:59:49 - Newser
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Sep 05 '25 |
Sale |
49.95 |
50,000 |
2,497,435 |
305,871 |
| Mosbrooker Eric | Chief Commercial Officer |
Sep 03 '25 |
Option Exercise |
9.05 |
6,563 |
59,395 |
61,563 |
| Mosbrooker Eric | Chief Commercial Officer |
Sep 03 '25 |
Sale |
47.07 |
6,563 |
308,936 |
55,000 |
1.08%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):